From Casetext: Smarter Legal Research

In re Wellbutrin XL Antitrust Litig.

UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA
Aug 11, 2011
CIVIL ACTION NO. 08-2431 (direct) (E.D. Pa. Aug. 11, 2011)

Summary

stating utilizing the "before and after" methodology which produces a damages estimate that is based on deriving a benchmark for generic prices in the "but for world" based on the actual experience for branded and generic prices after entry

Summary of this case from In re Novartis & Par Antitrust Litig.

Opinion

CIVIL ACTION NO. 08-2431 (direct)

08-11-2011

In re: WELLBUTRIN XL ANTITRUST LITIGATION


ORDER

AND NOW, this 11th day of August, 2011, upon consideration of the Direct Purchaser Plaintiffs' Motion for Class Certification (Docket No. 134), the opposition, reply, sur-reply, supplemental opposition, and supplemental reply thereto, the accompanying expert declarations, the hearing on April 5, 2011, and for the reasons stated in a memorandum of today's date, IT IS HEREBY ORDERED that the motion is GRANTED IN PART AND DENIED IN PART. IT IS FURTHER ORDERED that:

1. The following direct purchaser litigation class is hereby certified pursuant to Federal Rule of Civil Procedure 23(a) and 23(b)(3): "All persons or entities in the United States and its territories who purchased Wellbutrin XL directly from any of the Defendants at any time during the period of November 14, 2005 through August 31, 2009 (the 'Class Period'). Excluded from the class are Defendants and their officers, directors, management, employees, parents, subsidiaries, and affiliates, and federal government entities. Further excluded from the class are persons or entities who have not purchased generic versions of Wellbutrin XL during the class period after the introduction of generic versions of Wellbutrin XL."

2. Class claims, issues, and defenses are those incorporated into the Court's memorandum of today's date as well as the affirmative defenses raised in the defendants' answers. See Docket Nos. 83, 84.

3. Professional Drug Company, Inc. is hereby appointed representative of the direct purchaser class.

4. The following firms are hereby appointed as counsel to the direct purchaser class:

Co-lead Counsel

Hagens Berman Sobol Shapiro, LLP Thomas M. Sobol, Esquire
David S. Nalven, Esquire
Berger & Montague, P.C.
David F. Sorenson, Esquire

Liaison Counsel

Rodanast, P.C.
Joseph F. Roda, Esquire
Dianne M. Nast, Esquire
Jennifer S. Snyder, Esquire

Additional Class Counsel

Faruqi & Faruqi, LLP
Peter Kohn, Esquire
Taus, Cebulash, and Landau, LLP
Barry Taus, Esquire
Archana Tamoshounas, Esquire
Don Barrett, P.A.
Don Barrett, Esquire

5. Within 30 days of the date of this Order, the parties shall submit an agreed upon proposed notice program and forms of notice to class members. If the parties are unable to agree as to the proposed notice program and/or forms of notice, they shall submit separate proposals.

BY THE COURT:

MARY A. McLAUGHLIN, J.


Summaries of

In re Wellbutrin XL Antitrust Litig.

UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA
Aug 11, 2011
CIVIL ACTION NO. 08-2431 (direct) (E.D. Pa. Aug. 11, 2011)

stating utilizing the "before and after" methodology which produces a damages estimate that is based on deriving a benchmark for generic prices in the "but for world" based on the actual experience for branded and generic prices after entry

Summary of this case from In re Novartis & Par Antitrust Litig.

coming to this conclusion in a case involving 30 entities, which were located in 14 different states and Puerto Rico

Summary of this case from Ortez v. Michael P. Morton, P.A.
Case details for

In re Wellbutrin XL Antitrust Litig.

Case Details

Full title:In re: WELLBUTRIN XL ANTITRUST LITIGATION

Court:UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

Date published: Aug 11, 2011

Citations

CIVIL ACTION NO. 08-2431 (direct) (E.D. Pa. Aug. 11, 2011)

Citing Cases

In re Modafinil Antitrust Litig.

In analyzing whether joinder was impracticable, the District Court examined five factors: “(1) judicial…

Value Drug Co. v. Takeda Pharm., U.S.A.

Judge McLaughlin found judicial economy favored class certification of thirty-three members in In re…